Evidence map›Paper›PMID 37474666›Full record

ArticleScientific reports2023

A fast, low-cost, robust and high-throughput method for viral nucleic acid isolation based on NAxtra magnetic nanoparticles.

Erlend Ravlo, Mirta Mittelstedt Leal de Sousa, Lise Lima Andersen, Mona Holberg-Petersen, Ingvild Klundby, Per Arne Aas, Lars Hagen, Sten Even Erlandsen, Janne Fossum Malmring, Zeeshan Ali and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Erlend RavloDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Mirta Mittelstedt Leal de SousaDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Lise Lima AndersenDepartment of Microbiology, Oslo University Hospital and University of Oslo, Oslo, Norway.
Mona Holberg-PetersenDepartment of Microbiology, Oslo University Hospital and University of Oslo, Oslo, Norway.
Ingvild KlundbyDepartment of Microbiology, Oslo University Hospital and University of Oslo, Oslo, Norway.
Per Arne AasDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Lars HagenDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Sten Even ErlandsenLybe Scientific, Erling Skjalgssons gate 1, 7030, Trondheim, Norway.
Janne Fossum MalmringDepartment of Medical Microbiology, St. Olavs Hospital, 7006, Trondheim, Norway.
Zeeshan AliParticle Engineering Centre, Department of Chemical Engineering, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Anuvansh SharmaParticle Engineering Centre, Department of Chemical Engineering, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Vegar OttesenParticle Engineering Centre, Department of Chemical Engineering, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Sulalit BandyopadhyayParticle Engineering Centre, Department of Chemical Engineering, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Magnar BjøråsDepartment of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway. magnar.bjoras@ntnu.no.
Norwegian University of Science and Technology · NOUniversity of Oslo · NOElectromagnetic Geoservices (Norway) · NOOslo University Hospital · NOSt Olav's University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The year of 2020 was profoundly marked by a global pandemic caused by a strain of coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19). To control disease spread, a key strategy adopted by many countries was the regular testing of individuals for infection. This led to the rapid development of diagnostic testing technologies. In Norway, within a week, our group developed a test kit to quickly isolate viral RNA and safely detect SARS-CoV-2 infection with sensitivity comparable to available kits. Herein, the procedure employed for the detection of SARS-CoV-2 in swab samples from patients using the NTNU-COVID-19 test kit is described in detail. This procedure, based on NAxtra magnetic nanoparticles and an optimized nucleic acid extraction procedure, is robust, reliable, and straightforward, providing high-quality nucleic acids within 14 min. The NAxtra protocol is adaptable and was further validated for extraction of DNA and RNA from other types of viruses. A comparison of the protocol on different liquid handling systems is also presented. Due to the simplicity and low cost of this method, implementation of this technology to diagnose virus infections on a clinical setting would benefit health care systems, promoting sustainability.

Indexed as

COVID-19Magnetite NanoparticlesNucleic AcidsCOVID-19 TestingHumansRNA, ViralSARS-CoV-2Sensitivity and SpecificityMagnetite NanoparticlesNucleic AcidsRNA, Viral

Identifiers

PMID37474666
PMCPMC10359305
OpenAlexW4384924434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.